arrow
J

José Luis Perez-Gracia

university of navarra
H指数:64
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

作者更正: 预防性TNF阻断在双重CTLA-4和PD-1免疫疗法中的功效和毒性

Nature
IF48.5
2025-10-010
OAAI
Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

PD-1、LAG-3和TIM-3在肿瘤内CD8 T细胞上的表达与接受阿替利珠单抗治疗的晚期尿路上皮癌患者治疗反应的相关性:一项真实世界证据生物标志物研究

2025-08-080
OAAI
Variants of the MRGPRX2 Gene Found in Patients With Hypersensitivity to Quinolones and Vancomycin Show Amplified and Drug-Specific Activation Responses In Vitro

在奎诺酮类和万古霉素高敏患者中发现的MRGPRX2基因变体,显示出体外放大的且药物特异性的激活反应。

2025-05-010
OAAI
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

2024-12-010
PRE
Analysis of individuals presenting phenotypes of extreme high and low risk of developing tobbacco-induced lung cáncer.
2024-10-300
PRE
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

诱导avelumab,然后进行化学免疫疗法和维持与单独化疗作为顺式不合格转移性尿路上皮癌的一线治疗 (INDUCOMAIN): 一项随机II期研究

2024-09-010
OAAI
Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
2024-04-010
OAAI
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer
2023-06-203
OA
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

可溶性CD137作为监测激动剂CD137免疫疗法的动态生物标志物

2022-03-0211
OAAI
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
2022-03-0161
PRE